A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction.
Phase of Trial: Phase II
Latest Information Update: 25 Dec 2014
At a glance
- Drugs Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms SUCON
- 10 Dec 2009 Primary endpoint 'Progression free survival rate' has not been met.
- 10 Dec 2009 Results were presented at the 32nd Annual San Antonio Breast Cancer Symposium.
- 17 Nov 2009 Actual patient number (55) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History